Matches in SemOpenAlex for { <https://semopenalex.org/work/W2097118471> ?p ?o ?g. }
- W2097118471 endingPage "2659" @default.
- W2097118471 startingPage "2646" @default.
- W2097118471 abstract "Sorafenib is a multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma (HCC). However, therapeutic response to sorafenib was not equal among HCC patients. Here we present a novel system to provide quantitative information concerning sorafenib-related targets by simultaneous detection of phosphorylated ERK (pERK) and pAkt expressions in circulating tumor cells (CTCs) isolated from HCC patients. Our results showed that 90.0% of patients had a molecular classification of tissues concordant with that of CTCs. CTC counts showed a shaper decline in patients with pERK+/pAkt- CTCs after two weeks of sorafenib treatment (P < 0.01). Disease control rates were significantly different between patients with pERK+/pAkt- CTCs (11/15; 73.3%) and those without (13/44; 29.5%) (P < 0.05). Univariate and multivariate analysis indicated pERK+/pAkt- CTCs as an independent predictive factor of progression-free survival (PFS) (hazard ratio = 9.389; P < 0.01). PFS correlated with the proportion of pERK+/pAkt- CTCs (r = 0.968, P < 0.01), and was higher in patients with ≥ 40% pERK+/pAkt- CTCs compared to those with < 40% (8.4 vs. 1.3 mo; P < 0.05). In a validation set of twenty HCC patients, CTCs from patients with ≥ 40% pERK+/pAkt- CTCs had significantly higher inhibition rates of spheroid formation compared to those with < 40% (61.2 vs. 19.8%; P < 0.01). Our findings demonstrated that CTCs can be used in place of tumor tissue for characterization of pERK/pAkt expression. pERK+/pAkt- CTCs are most sensitive to sorafenib and an independent predictive factor of PFS in HCC patients treated with sorafenib." @default.
- W2097118471 created "2016-06-24" @default.
- W2097118471 creator A5008055721 @default.
- W2097118471 creator A5020079804 @default.
- W2097118471 creator A5023819550 @default.
- W2097118471 creator A5025195435 @default.
- W2097118471 creator A5025329094 @default.
- W2097118471 creator A5026465544 @default.
- W2097118471 creator A5042397011 @default.
- W2097118471 creator A5044871527 @default.
- W2097118471 creator A5053045844 @default.
- W2097118471 creator A5062623411 @default.
- W2097118471 creator A5069831074 @default.
- W2097118471 creator A5085279249 @default.
- W2097118471 date "2015-10-26" @default.
- W2097118471 modified "2023-10-18" @default.
- W2097118471 title "pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma" @default.
- W2097118471 cites W1553842589 @default.
- W2097118471 cites W1969988478 @default.
- W2097118471 cites W1970730989 @default.
- W2097118471 cites W1971146759 @default.
- W2097118471 cites W1971837077 @default.
- W2097118471 cites W1992609671 @default.
- W2097118471 cites W1994193851 @default.
- W2097118471 cites W1994356780 @default.
- W2097118471 cites W1996660594 @default.
- W2097118471 cites W2012564445 @default.
- W2097118471 cites W2016898759 @default.
- W2097118471 cites W2023933362 @default.
- W2097118471 cites W2024450952 @default.
- W2097118471 cites W2027335594 @default.
- W2097118471 cites W2028846086 @default.
- W2097118471 cites W2037286749 @default.
- W2097118471 cites W2037440964 @default.
- W2097118471 cites W2045336712 @default.
- W2097118471 cites W2051684210 @default.
- W2097118471 cites W2057559442 @default.
- W2097118471 cites W2061200917 @default.
- W2097118471 cites W2061746936 @default.
- W2097118471 cites W2063488708 @default.
- W2097118471 cites W2068638436 @default.
- W2097118471 cites W2073270386 @default.
- W2097118471 cites W2079077102 @default.
- W2097118471 cites W2096201751 @default.
- W2097118471 cites W2100131642 @default.
- W2097118471 cites W2102942095 @default.
- W2097118471 cites W2106181914 @default.
- W2097118471 cites W2110735634 @default.
- W2097118471 cites W2111070218 @default.
- W2097118471 cites W2112796039 @default.
- W2097118471 cites W2118645411 @default.
- W2097118471 cites W2119242310 @default.
- W2097118471 cites W2120967735 @default.
- W2097118471 cites W2126508950 @default.
- W2097118471 cites W2128153851 @default.
- W2097118471 cites W2138877493 @default.
- W2097118471 cites W2139799027 @default.
- W2097118471 cites W2141358606 @default.
- W2097118471 cites W2147909933 @default.
- W2097118471 cites W2155008430 @default.
- W2097118471 cites W2156871508 @default.
- W2097118471 cites W2165708858 @default.
- W2097118471 cites W2414273656 @default.
- W2097118471 cites W311872075 @default.
- W2097118471 cites W4243625103 @default.
- W2097118471 doi "https://doi.org/10.18632/oncotarget.6104" @default.
- W2097118471 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4823061" @default.
- W2097118471 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26544731" @default.
- W2097118471 hasPublicationYear "2015" @default.
- W2097118471 type Work @default.
- W2097118471 sameAs 2097118471 @default.
- W2097118471 citedByCount "45" @default.
- W2097118471 countsByYear W20971184712016 @default.
- W2097118471 countsByYear W20971184712017 @default.
- W2097118471 countsByYear W20971184712018 @default.
- W2097118471 countsByYear W20971184712019 @default.
- W2097118471 countsByYear W20971184712020 @default.
- W2097118471 countsByYear W20971184712021 @default.
- W2097118471 countsByYear W20971184712022 @default.
- W2097118471 countsByYear W20971184712023 @default.
- W2097118471 crossrefType "journal-article" @default.
- W2097118471 hasAuthorship W2097118471A5008055721 @default.
- W2097118471 hasAuthorship W2097118471A5020079804 @default.
- W2097118471 hasAuthorship W2097118471A5023819550 @default.
- W2097118471 hasAuthorship W2097118471A5025195435 @default.
- W2097118471 hasAuthorship W2097118471A5025329094 @default.
- W2097118471 hasAuthorship W2097118471A5026465544 @default.
- W2097118471 hasAuthorship W2097118471A5042397011 @default.
- W2097118471 hasAuthorship W2097118471A5044871527 @default.
- W2097118471 hasAuthorship W2097118471A5053045844 @default.
- W2097118471 hasAuthorship W2097118471A5062623411 @default.
- W2097118471 hasAuthorship W2097118471A5069831074 @default.
- W2097118471 hasAuthorship W2097118471A5085279249 @default.
- W2097118471 hasBestOaLocation W20971184711 @default.
- W2097118471 hasConcept C121608353 @default.
- W2097118471 hasConcept C126322002 @default.
- W2097118471 hasConcept C143998085 @default.
- W2097118471 hasConcept C207103383 @default.